Alternatives to calcineurin inhibition in renal transplantation: Belatacept, the first co-stimulation blocker

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 625-636

  Poirier, Nicolas ^a,b,c   Blancho, Gilles ^a,b,c   Vanhove, Bernard ^a,b,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

co stimulation blockade; CTLA4Ig; kidney transplantation; T cell activation

Indexed keywords

ABATACEPT; ALEFACEPT; BELATACEPT; CALCINEURIN; CD28 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; IMMUNOGLOBULIN G1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AUTOIMMUNITY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; CALCINEURIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG APPROVAL; DRUG DISCOVERY; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION;

EID: 77957567039     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.57     Document Type: Review

References (88)

1. Samaniego M, Becker BN, Djamali A: Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat. Clin. Pract. Nephrol. 2, 688-699 (2006).
2. Bostom AD, Brown RS Jr, Chavers BM et al.: Prevention of post-transplant cardiovascular disease - report and recommendations of an ad hoc group. Am. J. Transplant. 2, 491-500 (2002).
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349, 2326-2333 (2003). □ Incremental damage to nephrons leading to chronic allograft nephropathy, the cause of kidney transplant failure, is caused by immunologic and nonimmunologic events.
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 3, 178-185 (2003).
5. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J: A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am. J. Transplant. 8, 307-316 (2008).
6. Ekberg H, Tedesco-Silva H, Demirbas A et al.: Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007).
7. Ekberg H, Grinyo J, Nashan B et al.: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am. J. Transplant. 7, 560-570 (2007).
8. Wali RK, Weir MR: Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr. Opin. Organ Transplant. 13, 614-621 (2008).
9. Gregory CR, Kyles AE, Bernsteen L et al.: Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation 78, 681-685 (2004).
10. Budde K, Sommerer C, Becker T et al.: Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am. J. Transplant. 10(3), 571-581 (2010).
11. Quaedackers ME, Mol W, Korevaar SS et al.: Monitoring of the immunomodulatory effect of CP-690, 550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 88, 1002-1009 (2009).
12. Weaver TA, Charafeddine AH, Agarwal A et al.: Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat. Med. 15, 746-749 (2009).
13. Vincenti F, Kirk AD: What's next in the pipeline. Am. J. Transplant. 8, 1972-1981 (2008).
14. Scandling JD, Busque S, Dejbakhsh-Jones S et al.: Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358, 362-368 (2008). □ First demonstration in human that transplant tolerance can be intentionally achieved by creating a stable mixed hematopoietic chimerism.
15. Kawai T, Cosimi AB, Spitzer TR et al.: HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353-361 (2008). □ First demonstration that transplant tolerance can be intentionally achieved in humans by inducing transient mixed chimerism with the use of a nonmyeloablative preparative regimen.
16. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991). □ Seminal demonstration that CTLA4 is able to bind the B7 counter receptor.
17. Dumont FJ: Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. 6, 318-330 (2004).
18. Larsen CP, Pearson TC, Adams AB et al.: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453 (2005).
19. Acuto O, Michel F: CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3, 939-951 (2003).
20. Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A: Akt provides the CD28 co-stimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines. Nat. Immunol. 2, 37-44 (2001).
21. Boise LH, Minn AJ, Noel PJ et al.: CD28 co-stimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3, 87-98 (1995).
22. Latek R, Fleener C, Lamian V et al.: Assessment of belatacept-mediated co-stimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 87, 926-933 (2009).
23. Collins AV, Brodie DW, Gilbert RJ et al.: The interaction properties of co-stimulatory molecules revisited. Immunity 17, 201-210 (2002).
24. Tivol EA, Borriello F, Schweitzer AN, Lynch W P, Bluestone JA, Sharpe AH: Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4. Immunity 3, 541-547 (1995). □ One of the strongest proofs that CTLA4 is a physiological brake for T-cell expansion.
25. Waterhouse P, Penninger JM, Timms E et al.: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988 (1995). □ One of the strongest proofs that CTLA4 is a physiological brake for T-cell expansion.
26. Alegre ML, Noel PJ, Eisfelder BJ et al.: Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157, 4762-4770 (1996).
27. Carreno BM, Bennett F, Chau TA et al.: CTLA4 (CD152) can inhibit T-cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165, 1352-1356 (2000).
28. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW: Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA4. Science 272, 1170-1173 (1996).
29. Lee KM, Chuang E, Griffin M et al.: Molecular basis of T cell inactivation by CTLA4. Science 282, 2263-2266 (1998).
30. Martin M, Schneider H, Azouz A, Rudd CE: Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J. Exp. Med. 194, 1675-1681 (2001).
31. Olsson C, Riesbeck K, Dohlsten M, Michaelsson E: CTLA4 ligation suppresses CD28-induced NF-κB and AP-1 activity in mouse T cell blasts. J. Biol. Chem. 274, 14400-14405 (1999).
32. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP: CTLA4-Mediated inhibition of early events of T cell proliferation. J. Immunol. 162, 5813-5820 (1999).
33. Egen JG, Kuhns MS, Allison JP: CTLA4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
34. Krummel MF, Allison JP: CTLA4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533-2540 (1996).
35. + T lymphocytes induced by CTLA4 crosslinking. Proc. Natl Acad. Sci. USA 95, 10083-10088 (1998).
36. + T cells. J. Exp. Med. 188, 1849-1857 (1998).
37. Gomes NA, Gattass CR, Barreto-De-Souza V, Wilson ME, Dos Reis GA: TGF-β mediates CTLA4 suppression of cellular immunity in murine kalaazar. J. Immunol. 164, 2001-2008 (2000).
38. Sullivan TJ, Letterio JJ, van Elsas A et al.: Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T-cell activation. Proc. Natl Acad. Sci. USA 98, 2587-2592 (2001).
39. Sansom DM, Manzotti CN, Zheng Y: What's the difference between CD80 and CD86? Trends Immunol. 24, 314-319 (2003).
40. Wing K, Onishi Y, Prieto-Martin P et al.: CTLA4 control over Foxp3+ regulatory T cell function. Science 322, 271-275 (2008). □ Demonstrates that CTLA4 is needed on Treg cells to maintain their suppressive activity in vivo.
41. Poirier N, Azimzadeh AM, Zhang T et al.: Inducing CTLA4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2(17), 17RA10 (2010). □ First preclinical demonstration of the induction of an immune regulation after kidney and heart graft by inhibiting CD28 and not CTLA4.
42. + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA 105, 10113-10118 (2008).
43. Chavez H, Beaudreuil S, Abbed K et al.: Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with belatacept mediated CD28-CD80/86 blockade. Transpl. Immunol. 17, 243-248 (2007).
44. Bluestone JA, Liu W, Yabu JM et al.: The effect of co-stimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 8, 2086-2096 (2008).
45. Schneider H, Downey J, Smith A et al.: Reversal of the TCR stop signal by CTLA4. Science 313, 1972-1975 (2006). □ Points out a novel role for CTLA4-B7 interaction; namely, the prevention of T-cell immobilization on antigen-presenting cells and blocking of the formation of immune synapses.
46. Schneider H, Smith X, Liu H, Bismuth G, Rudd CE: CTLA4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur. J. Immunol. 38, 40-47 (2008).
47. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 co-stimulatory molecule to inhibit T cell responses. Immunity 27, 111-122 (2007).
48. Butte MJ, Pena-Cruz V, Kim MJ, Freeman GJ, Sharpe AH: Interaction of human PD-L1 and B7-1. Mol Immunol. 45, 3567-3572 (2008).
49. Grohmann U, Orabona C, Fallarino F et al.: CTLA4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3, 1097-1101 (2002). □ Original, nonhumanized form of CTLA4-Ig is able to induce indoleamine 2, 3-dioxygenase in dendritic cells through a signal via B7. It might also constitute one of its physiological mechanisms of action.
50. Fallarino F, Grohmann U, Hwang KW et al.: Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212 (2003).
51. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774 (2004).
52. + T cells. Blood 105, 1574-1581 (2005).
53. Hill M, Zagani R, Voisine C, Usal C, Anegon I: Nitric oxide and indoleamine 2, 3-dioxygenase mediate CTLA4-Ig-induced survival in heart allografts in rats. Transplantation 84, 1060-1063 (2007).
54. Pree I, Bigenzahn S, Fuchs D et al.: CTLA4-Ig promotes the induction of hematopoietic chimerism and tolerance independently of indoleamine-2, 3-dioxygenase. Transplantation 83, 663-667 (2007).
55. Davis PM, Nadler SG, Stetsko DK, Suchard SJ: Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin. Immunol. 126, 38-47 (2008). □ Humanization and modifications brought to the Fc domain of CTLA4-Ig to make abatacept has abrogated the 'reverse signaling' that was described with CTLA4-Ig in [49].
56. Carman JA, Davis PM, Yang WP et al.: Abatacept does not induce direct gene expression changes in antigen-presenting cells. J. Clin. Immunol. 29, 479-489 (2009).
57. Bahri R, Naji A, Menier C et al.: Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J. Immunol. 183, 7054-7062 (2009). □ These data define a novel pathway by which CTLA4-Ig immunomodulates allogenic response through post-transcriptional regulation of HLA-G expression in dendritic cells.
58. Baliga P, Chavin KD, Qin L et al.: CTLA4-Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 58, 1082-1090 (1994).
59. Adams AB, Shirasugi N, Durham MM et al.: Calcineurin inhibitor-free CD28 blockadebased protocol protects allogeneic islets in nonhuman primates. Diabetes 51, 265-270 (2002).
60. Sayegh MH, Akalin E, Hancock WW et al.: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181, 1869-1874 (1995).
61. Olthoff KM, Da Chen X, Gelman A, Turka L, Shaked A: Adenovirus-mediated gene transfer of CTLA4-Ig to liver allografts results in prolonged survival and local T-cell anergy. Transplant. Proc. 29, 1030-1031 (1997).
62. + T cells. J. Immunol. 163, 2358-2362 (1999).
63. Matsumura Y, Zuo XJ, Prehn J et al.: Soluble CTLA4-Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines. Transplantation 59, 551-558 (1995).
64. Mathes DW, Randolph MA, Lee WP: Strategies for tolerance induction to composite tissue allografts. Microsurgery 20, 448-452 (2000).
65. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS: CTLA4-Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 58, 602-610 (1994).
66. Lew AM, Brady JL, Silva A, Coligan JE, Georgiou HM: Secretion of CTLA4-Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen. Transplantation 62, 83-89 (1996).
67. Lenschow DJ, Zeng Y, Thistlethwaite JR et al.: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257, 789-792 (1992).
68. Guillot C, Mathieu P, Coathalem H et al.: Tolerance to cardiac allografts via local and systemic mechanisms after adenovirusmediated CTLA4Ig expression. J. Immunol. 164, 5258-5268 (2000).
69. Page AJ, Ford ML, Kirk AD: Memory T-cell-specific therapeutics in organ transplantation. Curr. Opin. Organ Transplant. 14, 643-649 (2009).
70. Adams AB, Pearson TC, Larsen CP: Heterologous immunity: an overlooked barrier to tolerance. Immunol. Rev. 196, 147-160 (2003).
71. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815-3825 (1994).
72. Cross AH, Girard TJ, Giacoletto KS et al.: Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA4-Fc supports a key role for CD28 co-stimulation. J. Clin. Invest. 95, 2783-2789 (1995).
73. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4-Ig. Science 265, 1225-1227 (1994).
74. Kirk A, Harlan D, Amstrong N et al.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94, 8789-8794 (1997). □ Combination of CTLA4-Ig with anti-CD40 ligand antibodies is 100-times more effective than either drug alone in preventing T-cell activation.
75. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ: Abatacept binds to the Fc receptor CD64 but does not mediate complementdependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 34, 2204-2210 (2007).
76. Linsley PS, Nadler SG, Bajorath J et al.: Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA4). A disulfide-linked homodimer binds two CD86 molecules. J. Biol. Chem. 270, 15417-15424 (1995).
77. Larsen C, Durrbach A, Nashan B et al.: Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety. Presented at: American Transplant Congress. MA, USA, 14-19 May (2004).
78. Vincenti F, Muehlbacher F, Nashan B et al.: Co-stimulation blockade with LEA29Y in a calcineurin inhibitor-free maintenance regimen: 6 month efficacy and safety. Presented at: American Transplant Congress. MA, USA, 14-19 May (2004).
79. Vincenti F, Larsen C, Durrbach A et al.: Co-stimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353, 770-781 (2005). □ First clinical demonstration that belatacept can replace calcineurin inhibitors in kidney transplantation.
80. Vincenti F, Blancho G, Durrbach A et al.: Five-year results of a Phase II study with belatacept in renal transplantation. J. Am. Soc. Neph. DOI: 10.1681/ASN.2009111109 (2010) (Epub ahead of print).
81. Vincenti F, Charpentier B, Vanrenterghem Y et al.: A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535-546 (2010).
82. Abrams JR, Lebwohl MG, Guzzo CA et al.: CTLA4-Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243-1252 (1999).
83. Durrbach A, Pestana JM, Pearson T et al.: A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10, 547-557 (2010).
84. Adams AB, Shirasugi N, Jones TR et al.: Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 174, 542-550 (2005).
85. Russell ME, Hancock WW, Akalin E et al.: Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 co-stimulation by CTLA4-Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 97, 833-838 (1996).
86. Azuma H, Chandraker A, Nadeau K et al.: Blockade of T-cell co-stimulation prevents development of experimental chronic renal allograft rejection. Proc. Natl Acad. Sci. USA 93, 12439-12444 (1996).
87. Chandraker A, Azuma H, Nadeau K et al.: Late blockade of T cell co-stimulation interrupts progression of experimental chronic allograft rejection. J. Clin. Invest. 101, 2309-2318 (1998).
88. Kim KS, Denton MD, Chandraker A et al.: CD28-B7-mediated T cell co-stimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158, 977-986 (2001).